long term side effects of glp 1 agonists Adverse GLP-1 receptor agonists: Clinical Implications, regulatory perspectives, and future directions GLP-1 receptor agonists and next-generation

U.KuhnH

60,000 IU/month cholecalciferol), vitamin D supplementation led to a non-significant 9% reduction in major adverse cardiovascular events (MACE), driven primarily by myocardial infarction, while stroke outcomes remained unchanged (Thompson et al., 2023)

A modelling system to inform the revision of the Australian Guide to Healthy Eating

We recently reported the development of a Gs protein proximity assay that provides a direct, AMYR-selective, measurement of Gs protein recruitment and activation 22

The average SNR values in each VOI were substantially higher than those reported in the majority of MRS studies [23, 57]